Relievant Medsystems, Inc. news
Relievant Medsystems shared today that the company’s breakthrough chronic low back pain treatment, the Intracept Procedure, was featured on NBC’s TODAY this morning. The full segment can be viewed here.
“
Relievant Medsystems, a privately held medical device company transforming the treatment of Chronic Low Back Pain (CLBP), announced today that new Category I Current Procedural Terminology (CPT) codes for the Intracept Procedure are in effect as of January 1, 2022.
The new Category I codes for the Intracept Procedure are:
- 64628: Thermal destruction of intraosseous basivertebral nerve, including all imaging guidance; first two vertebral bodies lumbar or sacral; and
Relievant Medsystems, a privately held medical device company transforming the treatment of Chronic Low Back Pain (CLBP), today announced 24-month results from a Level 1, prospective, randomized, multi-center trial (INTRACEPT) that further validate the safety, effectiveness, and durability of the Intracept® Procedure for patients with vertebrogenic CLBP.
The study reported outcomes for patients in the Intracept Procedure treatment arm that completed a
Relievant Medsystems, a privately held medical device company transforming the treatment of Chronic Low Back Pain (CLBP), today announced the Centers for Disease Control and Prevention (CDC) has designated an International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) diagnosis code specifically for vertebrogenic low back pain. The new diagnosis code – M54.51 – will go into effect on October 1, 2021.
Vertebrogenic pain is a form of chronic l
Relievant Medsystems, a privately held medical device company transforming the treatment of Chronic Low Back Pain (CLBP), announced today the appointment of Dave Amerson to the Company’s Board of Directors.
“It is with great pleasure that I welcome Dave to our Board of Directors,” said Tyler Binney, President and Chief Executive Officer of Relievant. “Dave’s wealth of leadership experience and track record of commercial success make him an excellent addit